263251-78-1

263251-78-1 structure

Name: Tavilermide
Chemical Name: 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
CAS Number: 263251-78-1
Molecular Formula: C₂₄H₃₂N₆O₁₁
Molecular Weight: 580.54400
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Trk Receptor
Create Date: 2016-05-10 20:39:30
Modify Date: 2025-09-17 22:30:53
Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.

Name	3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
Synonyms	d-3 unii-nmg938vj6t Tavilermide

Description	Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Trk Receptor Research Areas >> Inflammation/Immunology
Target	TrkA[1]
In Vitro	Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF[1].
References	[1]. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85.